Cytokinetics, Incorporated announced it is scheduled to report its fourth-quarter results on February 24, 2026, at 4:00 PM Eastern Time. Following the announcement, senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates, which will be webcast on the company’s website. The company also provided an overview of its pipeline, including MYQORZO™ (aficamten) for hypertrophic cardiomyopathy, and investigational medicines omecamtiv mecarbil and ulacamten for heart failure.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Cytokinetics to Announce Fourth Quarter Results on February 24, 2026
Cytokinetics, Incorporated announced it is scheduled to report its fourth-quarter results on February 24, 2026, at 4:00 PM Eastern Time. Following the announcement, senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates, which will be webcast on the company’s website. The company also provided an overview of its pipeline, including MYQORZO™ (aficamten) for hypertrophic cardiomyopathy, and investigational medicines omecamtiv mecarbil and ulacamten for heart failure.